Genprex Inc

GNPX

Company Profile

  • Business description

    Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

  • Contact

    3300 Bee Cave Road
    Suite 650-227
    AustinTX78746
    USA

    T: +1 877 774-4679

    https://www.genprex.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    13

Stocks News & Analysis

stocks

Alphabet raises $80 billion for AI efforts

$10 billion private placement to Berkshire Hathaway as part of equity raise.
stocks

Undervalued ASX healthcare provider

Solid demand profile for global leader.
stocks

SpaceX: What investors need to know about its enormous upcoming IPO

Morningstar launches research coverage of SpaceX.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,026.506.200.07%
CAC 408,209.0962.500.77%
DAX 4025,124.17121.130.48%
Dow JONES (US)51,307.79228.910.45%
FTSE 10010,373.5134.560.33%
HKSE25,587.30451.02-1.73%
NASDAQ27,093.907.090.03%
Nikkei 22568,710.501,976.262.96%
NZX 50 Index13,133.6737.04-0.28%
S&P 5007,609.789.820.13%
S&P/ASX 2008,794.9015.100.17%
SSE Composite Index4,097.9422.840.56%

Market Movers